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The skeletal muscle Ca2 release channel/ryanodine
receptor (RyR1) contains 50 thiols per subunit. These
thiols have been grouped according to their reactivity/
responsiveness toward NO, O2, and glutathione, but the
molecular mechanism enabling redox active molecules
to modulate channel activity is poorly understood. In
the case of NO, very low concentrations (submicromo-
lar) activate RyR1 by S-nitrosylation of a single cysteine
residue (Cys-3635), which resides within a calmodulin
binding domain. S-Nitrosylation of Cys-3635 only takes
place at physiological tissue O2 tension (pO2; i.e. 10 mm
Hg) but not at pO2 150 mm Hg. Two explanations have
been offered for the loss of RyR1 responsiveness to NO
at ambient pO2, i.e. Cys-3635 is oxidized by O2 versus O2
subserves an allosteric function (Eu, J. P., Sun, J. H., Xu,
L., Stamler, J. S., and Meissner, G. (2000) Cell 102, 499–
509). Here we report that the NO donors NOC-12 and
S-nitrosoglutathione both activate RyR1 by release of
NO but do so independently of pO2. Moreover, NOC-12
activates the channel by S-nitrosylation of Cys-3635 and
thereby reverses channel inhibition by calmodulin. In
contrast, S-nitrosoglutathione activates RyR1 by oxida-
tion and S-nitrosylation of thiols other than Cys-3635
(and calmodulin is not involved). Our results suggest
that the effect of pO2 on RyR1 S-nitrosylation is exerted
through an allosteric mechanism.
The large, homotetrameric skeletal muscle Ca2 release
channel/ryanodine receptor (RyR1)1 contains several classes of
regulatory thiols. These classes are distinguished by reactivity
or responsiveness to O2 tension (pO2) (1, 2), redox active mol-
ecules such as glutathione (3) and nitric oxide (NO) (1), trans-
membrane glutathione redox potential (4), and allosteric effec-
tor molecules (Ca2, Mg2) (5). It has recently been shown that
cysteine 3635, which is localized to the calmodulin (CaM) bind-
ing domain of RyR1 (6–8), confers responsiveness to NO. In
contrast, the identities of the remaining regulatory thiols are
not known. NO forms a covalent bond with the thiol group of
Cys-3635 (i.e. S-nitrosylation) in vivo and thereby reverses the
inhibitory effect of CaM on the channel (6). Full-length RyR1
channels with an alanine residue substituted for Cys-3635 are
not S-nitrosylated by physiological concentrations of NO, and
channel activity is unaffected by NO. S-nitrosylation of Cys-
3635 only occurs at low O2 tension (pO2 10 mm Hg, compa-
rable with that found in skeletal muscle in vivo) (1, 6). At this
pO2, 6–8 (of 50) thiols per RyR1 subunit are actively main-
tained in the reduced state (1). Thus, one explanation for the
failure of NO to S-nitrosylate RyR1 at ambient pO2 is that
Cys-3635 is oxidized. An alternative possibility is that the
oxidation of pO2-sensitive thiols leads to a change in channel
conformation; in this state S-nitrosylation of Cys-3635 is unfa-
vorable. Alternatively stated, O2 is either serving as an oxidant
(of Cys-3635) or as an allosteric effector (of Cys-3635
reactivity).
NO donors, compounds capable of donating NO and redox
active forms thereof, are widely used to mimic the effects of NO
synthase (9). A number of these compounds are capable of
modulating RyR1 activity (1, 10–15). RyR1 contains a large
number of reactive thiols (1, 2), and the action of NO donors
may differ widely depending on the mechanisms and rates of
NO release, the chemistry of NO group transfer, the base
structure of the NO donor compound, and the reactivity of
substrate thiol. In particular, members of the S-nitrosothiol
(SNO) class of NO donors can modulate protein function by
transnitrosylation as well as NO release (16, 17). In contrast,
the NONOate class of NO donors is thought to be less suscep-
tible to transnitrosylation chemistry (18). It is important to
note, however, that NONOate compounds may directly interact
with proteins through polyamine recognition sites and/or
through ionic interactions.
In the present study, we examined the activation of the
skeletal muscle Ca2 release channel by NOC-12 and GSNO,
an endogenous S-nitrosothiol, and compared their effects to
solutions of NO. We found that both NOC-12 and GSNO acti-
vated RyR1 independently of O2 tension and that the NO
scavenger, C-PTIO, blocked the effects of both. But whereas
NOC-12 mediated its effects by S-nitrosylation of a single cys-
teine (Cys-3635), GSNO activation involved the S-nitrosylation
and oxidation of multiple thiols. Moreover, Cys-3635 was not
required for activation by GSNO. Thus, NO, NOC-12, and
GSNO activate the prototypic redox-sensitive RyR1 channel by
different mechanisms, and the effect of O2 tension on S-nitrosy-
lation by NO is best rationalized by an allosteric mechanism.
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EXPERIMENTAL PROCEDURES
Materials—[3H]Ryanodine was a product of PerkinElmer Life Sci-
ences. CaM was obtained from Sigma. NO donors, monobromobimane,
myosin light chain kinase-derived CaM binding peptide and anti-S-
nitrosocysteine polyclonal antibody were from Calbiochem, and leupep-
tin and Pefabloc (protease inhibitors) were from Roche Molecular Bio-
chemicals. An ECL detection reagent kit was from Amersham
Biosciences. NO gas (purity 99%, National Welders) was scrubbed to
remove O2 and nitrite by passing through an argon-purged column
filled with KOH pellets and then a solution of NaOH. The concentration
of NO was determined by a hemoglobin titration assay and an NO
electrode (WPI Instruments) as described (1). All other chemicals were
of analytical grade.
Sample Preparations—Skeletal muscle sarcoplasmic reticulum (SR)
vesicles enriched in RyR1 were prepared from rabbit skeletal muscle in
the presence of protease inhibitors (19). The construction and expres-
sion of wild type (WT) and C3635A mutant RyR1s have been described
(6). WT and C3635A RyR1s were expressed in HEK293 cells, and crude
membrane fractions were prepared as described (6).
Quantification of RyR1 Free Thiols and S-Nitrosothio1s—RyR1 free
thiol (SH) and SNO contents were determined by the monobromobi-
mane fluorescence method and a photolysis/chemiluminescence-based
NO detection assay, respectively (1).
Electrophoresis and Detection of S-Nitrosocysteine on Western Blots—
All procedures were performed under non-reducing conditions (6).
Membranes were incubated in 0.125 M KCl, 20 mM imidazole, pH7.0,
and 8 M free Ca2 for 1 h at 24 °C in room air in the absence and
presence of NOC-12 or GSNO. Protein samples were separated by
3–20% SDS-PAGE under non-reducing conditions and transferred to
polyvinylidene difluoride membranes. The membranes were blotted
with 5% nonfat milk in 0.05% Tween 20 phosphate-buffered 0.1 M saline
solution at 24 °C for 2 h and probed with anti-S-nitrosocysteine poly-
clonal antibody (Calbiochem; 1:500) and secondary peroxidase-conju-
gated anti-rabbit IgG antibody (Calbiochem; 1:2000). Anti-S-nitrosocys-
teine signals were detected with an ECL kit (Amersham Biosciences).
After that, the membranes were re-probed with anti-RyR1 monoclonal
antibody D110 (1:10) and peroxidase-conjugated anti-mouse IgG (Cal-
biochem, 1:2000) using the ECL detection method.
[3H]Ryanodine Binding—Functional effects of NO donors were de-
termined in [3H]ryanodine binding measurements as described (1). The
assay conditions of [3H]ryanodine binding are indicated in the legends
to Figs. 1, 2, and 4.
Single Channel Recordings—Single channel measurements were
performed at room air by fusing RyR1-containing membrane fractions
with Mueller-Rudin-type bilayers containing phosphatidylethano-
lamine, phosphatidylserine, and phosphatidylcholine in the ratio 5:3:2
(25 mg of total phospholipid per milliliter of n-decane) (1, 20). The side
of the bilayer to which the RyR1-containing membrane fractions were
added was defined as the cis (cytoplasmic) side. The trans (lumenal)
side of the bilayer was defined as ground. Single channels were re-
corded in the buffer solutions given in the legends to Figs. 3 and 5.
Measurement of the sensitivity of the channels to cytosolic Ca2 indi-
cated that in a majority of recordings (98%) the cytosolic side of RyR1
faced the cis side and the lumenal side faced the trans side of the
bilayer. Electrical signals were filtered at 2 kHz, digitized at 10 kHz,
and analyzed with a commercially available software package (pClamp
8.2, Axon Instruments, Foster City, CA). Po values in multichannel
recordings were calculated using the equation Po   iPo,i/N, where N
is the total number of channels, and Po,i is channel open probability of
the
ith channel.
Other Biochemical Assays—Free Ca2 concentrations were obtained
by including in the solutions the appropriate amounts of Ca2 and
EGTA as determined using the stability constants and computer pro-
gram published by Schoenmakers et al. (21). Free Ca2 concentrations
were verified with the use of a Ca2 selective electrode. The protein
concentrations were determined by the Amido Black method (22).
Data Analysis—Results are given as means  S.D. unless otherwise
indicated. Significance of differences of data was analyzed with Stu-
dent’s t test. Differences were regarded to be statistically significant at
*, p  0.05 and **, p  0.01.
RESULTS
Release of NO by NOC-12 and GSNO—NOC-12 releases two
NO molecules per donor (23), whereas GSNO releases only one
(24). An NO electrode was used to characterize the peak con-
centrations and the durations of NO release under conditions
employed in the [3H]ryanodine binding measurements.
NOC-12 (0.1 mM) and GSNO (0.1 mM) attained peak concen-
trations of 2.6  0.4 M and 1.4  0.3 M (n  3 each) with
TABLE I
Peak concentrations and half lifetimes of NO released by
NOC-12 and GSNO
The stock solutions of NO donors (10 mM) were prepared fresh, and
NO release by 0.1 mM each NO donor was recorded with a NO electrode
(WPI Instruments) in the buffer used for [3H]ryanodine binding at
24 °C in room air (pO2  150 mm Hg). The half-life time of 1 M NO
under this condition was 10 min (1).
FIG. 1. Effects of NO, NOC-12, and GSNO on [3H]ryanodine
binding to skeletal muscle SR vesicles in pO2 of 10 mm Hg (A)
and 150 mm Hg (B). Specific [3H]ryanodine binding to skeletal SR
vesicles was determined in 0.125 M KCl, 20 mM imidazole, pH7.0, 8 M
free Ca2, the indicated concentrations of NO (columns) and NO donors
(lines with symbols), and 5 nM [3H]ryanodine at 24 °C for 5 h in pO2 10
mm Hg (A) and pO2 150 mm Hg (B), respectively. Data are the
mean  S.D. of four to six experiments. *, p  0.05; **, p  0.01
compared with respective control without NO or NO donor.
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half-life times of 6.5 and 2.8 h, respectively (Table I). In a
majority of the experiments, we matched the NO peak concen-
trations by comparing the groups treated with 0.1 mM NOC-12
with those treated with 0.2 mM GSNO. There was no difference
in peak concentrations of NO released by either donor as a
function of pO2 (pO2 10 mm Hg versus 150 mm Hg) (data
not shown). The half-life time of NO was 10 min.
O2 Tension-independent Modulation of RyR1 by NOC-12 and
GSNO—Modulation of RyR1 by NO is O2 tension dependent;
only at a pO2 comparable with that found in skeletal muscle in
vivo (pO2 10 mm Hg) can physiological amounts of NO (sub-
micromolar) S-nitrosylate and activate RyR1 (1). In Fig. 1, SR
vesicles were treated with increasing concentrations of NO,
NOC-12, or GSNO, and RyR1 activities were determined by
[3H]ryanodine binding at pO2 10 mm Hg (Fig. 1A) or at pO2
150 mm Hg (Fig. 1B). Ryanodine is a highly specific plant
alkaloid that is widely used as a probe of channel activity
because of its preferential binding to the open channel states
(25, 26). As shown previously (1), only at pO2 10 mm Hg did
NO (1–10 M) cause a significant increase in [3H]ryanodine
binding (Fig. 1A). Elevated levels of NO were inhibitory at pO2
10 mm Hg. In striking contrast, NOC-12 and GSNO activated
RyR1 channel activity at either O2 tension. Control experi-
ments showed that NOC-12 and GSNO left to incubate for 48 h
at room air (i.e. spent compounds) were without effect on RyR1
channel activity (data not shown). Under both O2 tensions,
NOC-12 concentrations higher than 0.1 mM caused a slight
decrease in [3H]ryanodine binding, whereas GSNO concentra-
tions higher than 0.2 mM further increased [3H]ryanodine bind-
ing. Thus, in contrast to NO, both NOC-12- and GSNO-activa-
tion of RyR1 is independent of pO2 (over a wide range of NO
donor concentrations).
Modulation of RyR1 by NOC-12 Is Dependent on CaM,
whereas GSNO Modulation Is Not—The functional effects of
S-nitrosylation of RyR1 Cys-3635 by NO are CaM-dependent
(1, 6). At [Ca2] 1 M, the Ca2-bound form of CaM (CaCaM)
inhibits RyR1, whereas at [Ca2] 1 M the Ca2-free form of
CaM (apoCam) activates the receptor (27). We therefore as-
sessed the effects of the NO donors on [3H]ryanodine binding in
the presence or absence of both the Ca2-bound form of CaM
and the Ca2-free form of CaM. Sequestration of endogenous
CaM with a CaM binding peptide (28) caused an increase in
RyR1 channel activity over control at 8 M free Ca2 (Fig. 2A)
and a decrease at 0.3 M free Ca2 (Fig. 2B). NOC-12 caused an
increase in [3H]ryanodine binding in the presence of CaM but
not after CaM had been sequestered (Fig. 2, A and B). In
contrast, GSNO caused an additional enhancement of RyR1
channel activity even after endogenous CaM sequestration.
These results support the idea that NOC-12 controls RyR1 via
the S-nitrosylation of Cys-3635, which is found in the CaM
binding region of RyR1. On the other hand, redox modulation
by GSNO does not appear to be dependent on S-nitrosylation or
oxidation of Cys-3635. More definitive evidence for the role of
Cys-3635 in the redox modulation of RyR1 is given below using
a RyR1 construct with a Cys-3635 to Ala substitution.
Modulation of RyR1 Single Channel Activities by NOC-12
and GSNO—The ability of the two NO donors to activate RyR1
under ambient oxygen tension was confirmed in single channel
recordings. Skeletal SR vesicles were incorporated into planar
lipid bilayers, and single RyR1 channels were recorded with
Cs as the current carrier. As shown in Fig. 3A, 0.1 mM
NOC-12 significantly activated RyR1 channel in the presence
of 2 M free Ca2 and 1 M CaM. Similarly, 0.2 mM GSNO
FIG. 2. Effects of CaM, NOC-12, and GSNO on [3H]ryanodine
binding of skeletal muscle SR vesicles. Skeletal muscle SR vesicles
were pretreated in the presence of 100 M Ca2 without or with 1 M
CaM or 1 M CaM binding peptide (CaMBP) at 24 °C for 30 min.
Specific [3H]ryanodine binding was assayed at 8 M Ca2 (A) or 0.3 M
Ca2 (B) as described in Fig. 1 in the absence and presence of 0.1 mM
NOC-12 or 0.2 mM GSNO in pO2 150 mm Hg. Data are the mean 
S.D. of three to four experiments. *, p  0.05; **, p  0.01 compared
with controls without NO donor in each group.
FIG. 3. Effects of NOC-12 and GSNO on RyR1 activities. SR
vesicles were fused with lipid bilayers in pO2 150 mm Hg. Single RyR1
channel currents, shown as downward deflections from closed levels
(solid lines) to open levels (dotted lines), were recorded in symmetric
0.25 M CsCH3SO3, 10 mM cesium HEPES buffer, pH7.3, at a holding
potential of 35 mV. Top traces, control with 2 M free Ca2 and 1 M
CaM; bottom traces, after the addition of 0.1 mM NOC-12 (A) or 0.2 mM
GSNO (B) to the cytosolic side. C, normalized Po before and after the
addition of 0.1 mM NOC-12 or 0.2 mM GSNO. Data are the mean  S.E.
of the number of recordings indicated in parentheses. *, p  0.05
compared with control (without NO donors).
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activated the channel (Fig. 3B). Fig. 3C shows that the aver-
aged channel open probability (Po) of RyR1 tripled after the
addition of 0.1 mM NOC-12 or 0.2 mM GSNO. Thus, both [3H]ry-
anodine binding and single channel measurements show that
under comparable conditions these two NO donors activate the
RyR1 to the same extent.
Redox-related Basis of RyR1 Modulation by NOC-12 and
GSNO—We next determined whether modulation of RyR1 by
NO donors involved the formation of a single SNO per RyR1
subunit, as was shown previously for NO at pO2 10 mm Hg
(1). We thus determined both the free thiol and SNO content of
RyR1s treated with NOC-12 or GSNO at pO2 150 mm Hg.
Exposure of SR vesicles to 0.1 or 1.0 mM NOC-12 increased
[3H]ryanodine binding to a similar extent and reduced the
RyR1 thiol content by 1 per RyR1 subunit, which was ac-
counted for by the formation of 1 SNO per RyR1 subunit
(Table II). The stoichiometry of 1 SNO/RyR1 subunit agreed
with that obtained by exposure to 0.75 M NO at pO2 10 mm
Hg (1). 0.1 mM NOC-12 optimally activated RyR1 in single
channel recordings in less than 1 min (Fig. 3A).
In contrast to NOC-12, 0.2 mM GSNO activated RyR1 at
ambient O2 tension via the S-nitrosylation or oxidation of mul-
tiple thiols or a combination of both redox-based modifications.
As shown in Table II, 0.2 mM GSNO S-nitrosylated approxi-
mately two RyR1 thiols in addition to oxidizing approximately
two thiols per RyR1 subunit (loss of approximately four thiols
per RyR1 subunit). At an elevated concentration (1.0 mM),
GSNO further increased the level of [3H]ryanodine binding and
S-nitrosylated approximately three thiols and oxidized approx-
imately four thiols (loss of approximately seven thiols/RyR1
subunit). Both oxidation and S-nitrosylation of RyR1 by GSNO
(and S-nitrosylation by NOC-12) were prevented in the pres-
ence of 5 mM reduced glutathione (not shown).
We considered the possibility that GSNO S-nitrosylates
RyR1 via transnitrosylation using C-PTIO, a NO scavenger,
and NOC-12 as a control. NOC-12 (0.1 mM) no longer had any
effect on RyR1 in the presence of 0.1 mM C-PTIO, neither
S-nitrosylating nor activating RyR1 (not shown). Similarly, 0.1
mM C-PTIO eliminated RyR1 S-nitrosylation and activation by
0.2 mM GSNO (not shown). These results suggest that S-ni-
trosylation of RyR1 by GSNO is dependent on release of NO, as
is the release of NO from NOC-12. We caution, nevertheless,
that C-PTIO may have other effects, including scavenging and
generating additional reactive radicals.
Cysteine 3635 Is Critical for RyR1 Modulation by NOC-12
but Not by GSNO—The aforementioned data using SR vesicles
suggest that at ambient pO2 NOC-12 S-nitrosylates Cys-3635
and activates RyR1 by antagonizing the inhibitory effect of
CaM. In contrast, GSNO works by a different mechanism. We
tested this hypothesis using a strategy that was previously
employed to demonstrate selective modification of Cys-3635 by
NO (6). Full-length WT or single-site C3635A RyR1 mutant
channels were expressed in HEK293 cells. Membranous frac-
tions containing WT and C3635A mutant RyR1s were isolated
from the HEK293 cells, and the effects of the two NO donors
were assessed at pO2 150 mm Hg in [
3H]ryanodine binding
(Fig. 4) and in single channel measurements (Fig. 5). NOC-12
had no effect on the mutant RyR1 (Figs. 4A and 5, A and C),
whereas the GSNO effect was preserved (Figs. 4B and 5, B and
FIG. 4. Effects of NOC-12 and GSNO on WT RyR1 and C3635A
RyR1 activities. Specific [3H]ryanodine binding to membrane frac-
tions prepared from HEK293 cells expressing WT or C3635A RyR1s
was determined in 8 M free Ca2 medium as described in the Fig. 1
legend in the presence of indicated concentrations of NOC-12 (A) or
GSNO (B) in pO2 150 mm Hg. [
3H]Ryanodine binding data are the
mean  S.D. of three to five experiments. *, p  0.05; **, p  0.01,
compared with each control (without NO donors).
TABLE II
Free thiol (SH) and S-nitrosothiol (SNO) contents of RyR1 and [3H]ryanodine binding levels in the absence and presence of NOC-12 and GSNO
The amounts of free thiols (SH) and S-nitrosothiols (SNO) of RyR1 were assayed in pO2  150 mm Hg by monobromobimane fluorescence and
the photolysis/chemiluminescence NO detection method, respectively (1). For functional comparison, [3H]ryanodine binding was carried out under
the same conditions (with 8 M free Ca2). Data are mean  S.D. of number of experiments given in parentheses.





Normal 29.3  1.2 (7) 0.41  0.02 (6) 0.56  0.05 (6)
NOC-12
0.1 mM 28.1  1.0 (6) 1.43  0.21 (6) 0.78  0.05 (3)
1.0 mM 28.2  0.2 (3) 1.45  0.36 (3) 0.74  0.08 (3)
GSNO
0.2 mM 25.5  0.8 (5) 2.05  0.35 (4) 0.72  0.03 (3)
1.0 mM 22.6  1.2 (5) 3.02  0.24 (4) 0.83  0.06 (3)
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C). The failure of NOC-12 to activate RyR1 C3635A was not
due to a lack of CaM binding, because the C3635A mutation
does not eliminate modulation of RyR1 activity by CaM (6, 8).
We used an anti-nitrosocysteine polyclonal antibody to de-
termine whether NOC-12 and GSNO S-nitrosylated the RyR1
C3635A mutant channel. We first confirmed that NO increased
the immunoreactivity of the native and WT RyR1s in pO2 10
mm Hg but not pO2 150 mm Hg (6) (not shown). NO did not,
however, increase immunoreactivity of the C3635A mutant
RyR1 at either oxygen tension. A weak signal was detected by
the antibody in the control samples (without NO donor) in a
region of the immunoblots containing the RyR1 (Fig. 6, left
panel), as determined by an anti-RyR1 antibody (Fig. 6, right
panel). NOC-12 (0.1 and 1.0 mM) produced virtually the same
signal as NO (6) but in ambient pO2, thus increasing the level
of S-nitrosylation of native and WT RyR1s but not of C3535A
RyR1. Specificity of S-nitrosylation was proven by showing that
prior treatment with HgCl2 nearly eliminated the signal (not
shown). In contrast, 0.2 and 1.0 mM GSNO did not noticeably
increase the low levels of endogenous immunoreactivity. Taken
together, the data of Figs. 4–6 suggest that NOC-12 and GSNO
affect the RyR1 by two different mechanisms, i.e. NOC-12 by
S-nitrosylation of Cys-3635 and GSNO by S-nitrosylation
and/or oxidation of an additional/alternative class of RyR1
thiols.
DISCUSSION
The massive (2,200 kDa) ryanodine receptors contain nu-
merous allosteric sites subserving multiple levels of control
(25). It has been firmly established that all three mammalian
ryanodine receptor isoforms are redox sensitive, i.e. the chan-
nels contain regulatory thiols whose oxidation or covalent mod-
ification alters their activities (1, 2, 29–32). These thiols (50/
subunit) have been grouped according to their differential
reactivities toward NO, O2, and glutathione, which in turn may
be linked to binding of allosteric effectors (1, 2). We have
recently shown that NO, at low pO2, selectively modifies Cys-
3635 (6). PO2 is dynamically linked to the redox state of a class
of 6–8 thiols. However, the identities of these regulatory thiols
and the mechanistic basis of the pO2 regulation of NO binding
(homotropic versus heterotropic) remain to be determined.
Here we have probed this question by taking advantage of the
different reactivities and properties of alternative classes of
NO donors.
Cysteine 3635 is part of a predicted hydrophobic motif for
S-nitrosylation (33) located within the RyR1 CaM binding do-
main (7, 8); NO regulation of RyR1 activity is thus CaM de-
pendent (1, 6). We posited that the inability of NO to S-nitrosy-
late Cys-3635 at ambient O2 tension is either due to Cys-3635
being oxidized (i.e. Cys-3635 is one of the 6–8 thiols) or to a
change in channel conformation brought about by the oxidative
posttranslational modification. As a first step to address this
question, we determined the dependence of NOC-12 and GSNO
on Cys-3635 and pO2. NOC-12 and GSNO had very similar
effects on RyR1 channel activity (at concentrations matched for
NO release), and neither compound showed O2 dependence
(pO2 10 mm Hg versus pO2 150 mm Hg). However, the
underlying mechanism of activation was quite different in each
case. GSNO activated RyR1 via poly-S-nitrosylation and/or
oxidation of RyR1 thiols. Cys-3635 and CaM were not essential
for activation. These data are highly reminiscent of the effects
of GSNO on cardiac muscle isoform of RyR (RyR2), except that
O2 and CaM dependence were not explored at that time (20).
NO and NOC-12 have little effects on RyR2.2 In stark contrast,
NOC-12 activates RyR1 via S-nitrosylation of Cys-3635, and
the increases in activity ([3H]ryanodine binding in intact SR) is
CaM dependent, as seen with NO. Specifically, the only modi-
fication of RyR1 by NOC-12 was nitrosylation of a single thiol,
2 J. Sun and G. Meissner, unpublished studies.
FIG. 5. Effects of NOC-12 on single channel activities of WT
RyR1 and C3635A RyR1. A and B, membrane fractions containing
WT and C3635A RyR1s were fused with lipid bilayers in pO2 150 mm
Hg. Left side, single channel currents of two WT RyR1 channels, shown
as downward deflections from closed levels (solid lines) to open levels
(dotted lines; the two dotted lines in each trace indicate the amplitude
of two channels), were recorded in symmetric 250 mM KCl, 20 mM
potassium Hepes buffer, pH 7.4, at holding potential of 35 mV. Top
traces, control with 2 M free Ca2 and 1 M CaM; bottom traces, after
the addition of 0.2 mM NOC-12 (A) or 0.2 mM GSNO (B) to the cytosolic
side. Right side, single channel currents of two C3635A RyR1 channels
recorded in same condition as WT RyR1. Top traces, control with 2 M
free Ca2 and 1 M CaM; bottom traces, after the addition of 0.2 mM
NOC-12 (A) or 0.2 mM GSNO (B) to the cytosolic side. C, normalized Po
before and after the addition of 0.2 mM NOC-12 or 0.2 mM GSNO. Data
are the mean  S.E. of the number of experiments indicated in paren-
theses. *, p  0.05, compared with control (without NO donors).
FIG. 6. Immunoblots for nitrosocysteine and RyR1. Skeletal SR
vesicles (A, 10 g protein/lane) and cell membrane fractions (B and C,
20 g protein per lane) containing WT RyR1 (B) or C3635A RyR1 (C)
were incubated for 1 h at 24 °C in pO2 150 mm Hg with 8 M free Ca
2
in the absence or presence of indicated concentrations of NOC-12 or
GSNO. The proteins were separated by 3–12% gradient SDS-PAGE and
transferred to polyvinylidene difluoride membranes overnight at 4 °C.
A polyclonal anti-S-nitrosocysteine antibody (left panel, 1:500 dilution)
was used to detect an S-nitrosylation signal in the protein band region
of RyR1 probed with D110 monoclonal anti-RyR1 (right panel, 1:10
dilution). The data are representative of three experiments.
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and full-length, heterogeneously expressed RyR1 with a
C3635A mutation was not activated. Unlike NO, however, S-
nitrosylation by NOC-12 is seen at high pO2. Thus we conclude
that Cys-3635 of RyR1 is not oxidized at ambient O2 tension.
Why NO and NOC-12 mediated S-nitrosylation differ in
their pO2-dependence remains unclear. NOC-12 evidently de-
pends on released NO, because its RyR1-activating effect was
inhibited by C-PTIO (a NO scavenger) and was not reproduced
by the spent compound. It is unlikely that differences in half-
life of NOC-12 versus NO (6 h versus 10 min, Table I) provide
an explanation, because the effect of NOC-12 in single channel
recordings was seen within 1 min. Instead, we favor the idea
that access of NO to the cysteine thiol is responsible for the
differences. Hydrophobic domains that concentrate nitrosylat-
ing equivalents and the quaternary structure of the target site
are both important determinants for S-nitrosylation (33, 34).
NOC-12 may interact with the RyR1 (ionic interactions of these
compounds are seen with other proteins),3 perhaps in a way
that is conducive to nitrosylation irrespective of RyR conforma-
tion. An interaction with the protein would also have the effect
of increasing the effective molarity of the NONOate, thereby
potentiating nitrosylation chemistry involving O2. In contrast,
access of solution NO (i.e. through the protein) to Cys-3635
might be available in the low pO2 conformation but blocked at
high pO2. The hydrophobic pocket where Cys-3635 resides may
even serve to concentrate NO/O2 to produce nitrosylating
equivalents. In this scenario, the allosteric function subserved
by low pO2 is 2-fold: 1) to produce a nitrosylation-responsive
conformation of the RyR1; and 2) to catalyze nitrosylation
chemistry (micellar catalysis).
An intriguing finding was that NOC-12 and GSNO operate
by different mechanisms. NO release from GSNO is evidently
necessary for activation of the RyR1, because the NO scavenger
C-PTIO blocked the effects of GSNO on the RyR1. Nonetheless,
it is premature to exclude transnitrosylation reactions of
GSNO, acting alone or in concert with released NO, in the
activating mechanism. Other explanations for GSNO effects
include the possibility that GSNO-mediated oxidation favors
the S-nitrosylation of a specific class of thiols (or vice versa). It
has recently been shown that proteins may have specific bind-
ing sites for GSNO, which would direct the chemistry to thiols
in its vicinity (35).
In summary, NO, NOC-12 and GSNO all activate RyR1 to
comparable degrees in [3H]ryanodine binding and single chan-
nel measurements. However, only the effect of NO is pO2-de-
pendent. Activation by both NO and NOC-12 involves the CaM-
dependent S-nitrosylation of Cys-3635, whereas GSNO
mediated activation (involving S-nitrosylation/oxidation of up
to seven RyR1 thiols) can occur independent of Cys-3635 and
CaM. Thus O2, NO, and GSNO react with different classes of
thiols, and the role of pO2 in RyR1 S-nitrosylation is likely
mediated through allostery.
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